Table 3.
The frequencies of the genotypes II, ID, and DD of the control and the subjects with PCa or BPH.
| Allele | Control | Affected | OR | 95% CI | p value | RR | 95% CI | p value |
|---|---|---|---|---|---|---|---|---|
| A. Control group versus PCa group | ||||||||
| DD/II | 27/8 | 19/7 | 0.80 | 0.25–2.60 | 0.716 | 0.95 | 0.71–1.27 | 0.719 |
| DD/ID | 27/34 | 19/43 | 0.56 | 0.27–1.17 | 0.120 | 0.69 | 0.43–1.11 | 0.124 |
| (DD + ID)/II | 61/8 | 62/7 | 1.16 | 0.40–3.40 | 0.785 | 1.02 | 0.90–1.14 | 0.785 |
| (II + ID)/DD | 42/27 | 50/19 | 1.69 | 0.83–3.46 | 0.150 | 1.19 | 0.94–1.51 | 0.152 |
| ID/(DD + II) | 34/35 | 43/26 | 1.70 | 0.86–3.35 | 0.124 | 1.26 | 0.94–1.71 | 0.127 |
|
| ||||||||
| B. Control group versus BPH group | ||||||||
| DD/II | 27/8 | 20/1 | 5.93 | 0.68–51.27 | 0.106 | 1.23 | 1.00–1.51 | 0.043∗ |
| DD/ID | 27/34 | 20/48 | 0.52 | 0.25–1.08 | 0.082 | 0.66 | 0.42–1.06 | 0.084 |
| (DD + ID)/II | 61/8 | 68/1 | 8.92 | 1.08–73.37 | 0.042∗ | 1.11 | 1.02–1.22 | 0.018∗ |
| (II + ID)/DD | 42/27 | 49/20 | 1.58 | 0.77–3.20 | 0.210 | 1.17 | 0.92–1.49 | 0.212 |
| ID/(DD + II) | 34/35 | 48/21 | 2.35 | 1.17–4.72 | 0.016∗ | 1.41 | 1.06–1.88 | 0.018∗ |
|
| ||||||||
| C. Control group versus the combined PCa and BPH (affected) groups | ||||||||
| DD/II | 27/8 | 39/8 | 1.44 | 0.48–4.32 | 0.512 | 1.08 | 0.86–1.34 | 0.520 |
| DD/ID | 27/34 | 39/91 | 0.54 | 0.29–1.01 | 0.055 | 0.68 | 0.46–0.99 | 0.048∗ |
| (DD + ID)/II | 61/8 | 130/8 | 2.13 | 0.76–5.95 | 0.148 | 1.07 | 0.97–1.17 | 0.190 |
| (II + ID)/DD | 42/27 | 99/39 | 1.63 | 0.88–3.00 | 0.115 | 1.18 | 0.95–1.46 | 0.136 |
| ID/(DD + II) | 34/35 | 91/47 | 1.99 | 1.10–3.59 | 0.021∗ | 1.34 | 1.02–1.75 | 0.032∗ |
∗Significant at the 0.05 level of significance.